Sponsored Links

EU tightens import controls on Chinese seafood

Fri Jun 29, 2007 10:32am EDT
 
[-] Text [+]

By Darren Ennis

BRUSSELS (Reuters) - European Union countries are stepping up safety controls on Chinese food imports following a U.S. crackdown on Chinese farm-raised catfish, shrimp and other seafood, the European Commission said on Friday.

The U.S. Food and Drug Administration said on Thursday it would not allow imports of the Chinese seafood until suppliers could prove shipments were free from harmful residues.

"We are currently reviewing the situation in respect of the U.S. decision, but we have asked our countries to be extra vigilant and they are stepping up their controls," a spokesman for the 27-country EU's executive arm said.

The U.S. FDA said there was no immediate threat to the public because the seafood contained low levels of the substances, but serious health problems could emerge if the products were consumed over long periods.

Catfish, basa, shrimp, dace and eel will not be allowed into the United States from China until the importer can show products meet U.S. requirements and safety standards.

U.S. officials have uncovered a series of unsafe products imported from China.

Earlier this year, melamine, a chemical used in plastics and fertilizer, surfaced in U.S. pet food, killing animals and prompting wide recalls.

The EU Commission spokesman said there had been an increase in the number of food products imported into the EU from China found to contain dangerous veterinary residues.

"We had three cases in 2006, while so far we have discovered nine cases this year under our rapid alert system, so this gives us the basis for our concern," the spokesman said.

 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
A customer shops for medicine at a Portland, Oregon drugstore July 31, 2005. REUTERS/Richard Clement RC/YH
Blame game slows growth of personalized medicine

Expectation has been building for a decade that an era of personalized medicine will transform the global drugs business, but the reality is a slow start and an angry blame game between scientists, marketers and regulators.  Full Article